放射免疫疗法的放射生物学：靶向非霍奇金淋巴瘤中的CD20 B细胞抗原

Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.

作者信息

Hernandez M Carmen, Knox Susan J

机构信息

Department of Radiation Oncology, Stanford University Medical Center, 269 Campus Drive West, Stanford, CA 94305, USA.

出版信息

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1274-87. doi: 10.1016/j.ijrobp.2004.02.065.

DOI:10.1016/j.ijrobp.2004.02.065

PMID:15275710

Abstract

The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies. The properties of the target, CD20, and the mechanisms of action of both the monoclonal antibodies and the associated exponentially decreasing low-dose-rate radiotherapy are described. The radiation dose and dose-rate effects are discussed and related to both the tumor responses and normal organ toxicity. Finally, the use of either unlabeled or radiolabeled anti-CD20 monoclonal antibodies as a component of combined modality therapy (including the sequential or concurrent use of sensitizers) and future directions of the field are discussed.

摘要

放射免疫疗法的放射生物学是用放射性标记的抗CD20单克隆抗体治疗B细胞非霍奇金淋巴瘤时毒性和疗效的重要决定因素。文中描述了靶点CD20的特性以及单克隆抗体和相关指数递减低剂量率放射疗法的作用机制。讨论了辐射剂量和剂量率效应，并将其与肿瘤反应和正常器官毒性联系起来。最后，讨论了使用未标记或放射性标记的抗CD20单克隆抗体作为联合治疗模式的一个组成部分（包括增敏剂的序贯或同步使用）以及该领域的未来发展方向。